@theAGU Interested in how geysers function and their academic value as volcano analogs? Join @ucdavis student Uthkarsh Das for an interesting talk on a novel theoretical model and laboratory validation of fluid motion in bubble trap geysers #AGU22 https://t.co/x4uaTA5ldF
✅ Just wrapped #CAP25 in Orlando — key takeaways:
•AI is moving from pilot to practice, with CAP + CHAI setting standards
•New research in molecular, renal, GI, & pulmonary pathology refining workflows & practice
Pathology’s future = human expertise + AI innovation.
#CAP25
Heading to Orlando for #CAP2025 — looking forward to insights on pathology innovations, precision medicine, and quality assurance. Excited to see how #AI is shaping diagnostics and the future of our labs.
Today, the U.S. FDA approved our targeted therapy in combination with chemotherapy as a first-line treatment for patients living with locally advanced or metastatic non-small cell #LungCancer with EGFR exon 20 insertion mutations: https://t.co/R1YI94raAA
Please take a minute to fill out the survey on #BiomarkerTesting. This will help understand the gaps, and define our efforts moving forward globally, to personalize therapy in #NSCLC@IASLC@karenkellymd@MattSmeltzer
https://t.co/CV1RyvWVhX
The U.S. FDA has granted full approval for our targeted therapy for patients with genetically defined, locally advanced, or metastatic urothelial carcinoma. Learn about our commitment to advancing the treatment of #BladderCancer: https://t.co/js32AK52SQ
@JNJInnovation has successfully submitted the MARIPOSA Phase 3 study to the FDA. 52 days since #DrCho presented these results at #ESMO2023. #NSCLC#MyCompany
https://t.co/kNj4FjzqAO
#NEWS: We announced topline results from the Phase 3 MARIPOSA study in patients with EGFR-mutated non-small cell lung cancer, an important step forward in our aim to advance treatment options for patients. https://t.co/9Yc75w4wTg #LungCancer#NSCLC
The @IASLC Corporate Roundtable met on 6/2/23 in Chicago, IL, to address barriers to access biomarker testing for advanced #NSCLC in diverse health care systems worldwide, focusing on the crucial need to increase testing for #lungcancer globally. #LCSM#ASCO23
UPDATE: Our submission to the U.S. FDA for a new targeted therapy for patients with BRCA-positive metastatic castration-resistant #ProstateCancer#mCRPC has received Priority Review. https://t.co/56gMkdGWQI